Leadership void at FDA generics office has US industry worried
This article was originally published in SRA
Executive Summary
With Greg Geba, the latest chief of the US Food and Drug Administration's Office of Generic Drugs, packing his bags on 15 March and leaving the agency after only eight months on the job, the head of the country’s generics lobbying group has voiced concern that the departure could bring disruption and distraction, resulting in the flow of information and guidance to manufacturers being blunted, with drug approvals ultimately slowed1-3.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.